Potential Public Health Impacts Of The Use Of Recombinant Bovine Somatotropin In Dairy Production

Table 1. Results from eight studies on the levels of IGF-1 in milk from rbGH-treated and untreated cows.

Company	Author, Year of Publication	Sample size (# of cows)	rbGH dosage (Amount, duration)	Equivalent dose (mg/14 day period	Length of experiment (days)	IGF-1 levels in milk increased
American Cyanimid	Schingoethe & Cleale, 1989	20	10.3 mg/14 day	144	113	N
Elanco	Schames & Karg, 1988	8	640 mg/28 days	320	118	Y
Elanco	Davis et. al, 1989	36	320 mg or 640 mg/28 days	160 or 320	30	N
Elanco	Coleman et. al, 1990	12	640 mg/28 days	320	56	N
Monsanto	FDA, 1993	18	500 mg/14 days	500	42	Y
Monsanto	Torkelson et. al, 1988	18	500 mg/14 days	500	42	Y
Monsanto	White et al., 1969	18	500 mg/14 days	500	42	Y
Monsanto	Miller, et. al, 1989	64	500 mg/14 days	500	140	Y

 

 Table 2. Effect of POSILAC on mastitis. Data from Kronfeld, 1997.

Period and parity	Mastitis cases/100 cows/252 days		Significance (p value)
	Control	Posilac
Pre-approval 8 trials, 487 cows
...Primiparous	21	37	0.015
...Multiparous	36	54	0.0021
...All	32	49	0.0001
*PAMP 28 trials, 1128 cows
...Primiparous	27	33	0.17
...Multiparous	44	59	0.0001
...All	37	49	0.0001
*Post-approval monitoring program